TG Therapeutics, Inc. (TGTX) Stock Analysis
A live, multi-source view of TG Therapeutics, Inc. (TGTX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Sector: Healthcare · Industry: Biotechnology · United States · 399 employees · tgtherapeutics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, TG Therapeutics, Inc. (TGTX) had a market capitalization of $8.57B, a trailing P/E of 20.4 (forward 18.9) and a beta of 1.66; the shares traded in a 52-week range of $26.76 – $59.30 (75.1% over the year).
- Market cap
- $8.57B
- Enterprise value
- $8.14B
- Trailing P/E
- 20.4
- Forward P/E
- 18.9
- PEG ratio
- 1.61
- Price / book
- 13.61
- EPS (trailing)
- $2.74
- EPS (forward)
- $2.96
- Payout ratio
- 0.0%
- 52-week range
- $26.76 – $59.30
- 52-week change
- 75.1%
- Beta
- 1.66
- Average volume
- 2.5M
- Shares outstanding
- 153.1M
- Short % of float
- 28.43%
- Profit margin
- 55.2%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, TG Therapeutics, Inc. (TGTX) last closed at $55.39 (the last completed close before that scan).
Technicals at the scan: RSI 56 (neutral territory), price +3.1% versus its 20-day average, 20-day versus 50-day average spread +0.3%, MACD histogram 0.09.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 69/100.
Next scheduled company event: in 52 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for TGTX in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
TGTX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls TG Therapeutics, Inc. (TGTX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TGTX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.